Stock Market Today: NFLX Drops, GRML Surges +75%, MSFT Down | Midday

Watch Full Video on YouTube: https://www.youtube.com/watch?v=Ud4KAKD4us4

Market Overview

We are two hours into the session and the market is bifurcating sharply: a biotech giant rewriting the obesity playbook, a micro-cap explorer riding a geopolitical tsunami, and a Swiss sneaker maker laying down a $7 billion revenue gauntlet. Volume is confirming conviction across the board.

Key Stock Movements

BFLY — MASSIVE INTRADAY REBOUND

Two hours into today's session, Butterfly Network is surging over eighteen percent! Despite headlines noting an executive share sale, filings confirm it was simply a routine tax-withholding transaction. Motley Fool has the latest breakdown.

CLDX — BIOTECH HEAVY VOLUME DIP

We are two hours into trading and Celldex Therapeutics is down over twelve percent. Investors are recalibrating ahead of pivotal phase two and three clinical readouts expected this fall, as highlighted in today's report from Zacks.

LPLA — SHARP MIDDAY PULLBACK

Two hours into the trading day, LPL Financial is slipping nine percent. Markets are navigating discrimination lawsuit headwinds alongside shifting cash management demand, according to coverage spotlighted by Simply Wall Street.

VKTX — MASSIVE OBESITY BREAKOUT

Viking Therapeutics is the undisputed star of the midday session, ripping nearly 25% on volume that suggests institutional FOMO is real. The catalyst is the VK2735 maintenance data—patients keeping 90 to 97% of their weight loss on monthly or biweekly dosing is a potential paradigm shift for adherence and payer coverage. This isn't just efficacy; it's convenience and durability, the two holy grails the Street has been pricing in for Eli Lilly and Novo Nordisk. With 19 analysts carrying a Strong Buy and a mean target north of $92, the setup is pristine for a test of the $125 high target if the afternoon holds. Watch the $85 level—former resistance, now critical support—for any pullback buyers.

Analysis: Phase 2 data shows 90-97% weight loss retention on monthly/biweekly dosing vs 61% placebo. Analyst mean target $92.39 (High $125). 19 Strong Buys. Volume confirming institutional accumulation.

GRAB — SUPER-APP VOLUME SURGE

Two hours in and Grab Holdings is bouncing over seven percent! The Southeast Asian super-app is capturing heavy retail interest following recent insider buying near historic lows, as detailed across Zacks and GuruFocus.

GRML — HISTORIC STRATEGIC EXPLOSION

Greenland Mines is up a staggering 76% on the Trump administration's new security framework for Greenland, which the market is instantly translating into a fast-track for rare earth permitting at Sarfartoq. This is pure speculative momentum—only one analyst on the Street with a $110 price target and zero formal rating—so treat this as a lottery ticket, not an investment. The license expansion to 454 square kilometers is the fundamental hook, but today's move is 100% geopolitical optionality. If you're long, use the VWAP as your trailing stop; liquidity will vanish the second headlines fade.

Analysis: US-Greenland security pact fuels strategic resource narrative. Sarfartoq license expanded to 454 km². Single analyst target $110. Extreme speculative caution advised—trade, don't invest.

XNDU — QUANTUM INTENSE VOLATILITY

Two hours into the market day, Xanadu Quantum is tumbling nearly eighteen percent. Despite ambitious targets of over one thousand logical qubits by 2031, trading remains volatile following optical loss updates reported by Stocktwits.

ONON — RECORD BUYBACK BREAKOUT

On Holding is delivering a masterclass in compounder execution, up 11% after an Investor Day that handed the Street a $1 billion buyback and a CHF 5.6 billion revenue target by 2029 implying 20%+ EBITDA CAGR. The 65% gross margin and 22% EBITDA margin targets are best-in-class for footwear, and the $65 million tariff refund tailwind for Q3 is a nice near-term cherry on top. Stifel at $41 and Goldman at $42 look conservative against the $72 high target if management hits these numbers. This is a 'buy the dip' name on any afternoon profit-taking toward the $40 handle.

Analysis: Targets: High-teens sales CAGR, 65%+ gross margin, 22%+ EBITDA margin. $1B buyback authorized. Stifel $41, Goldman $42 targets. Mean target $42.92. Quality compounder re-rating.

NU — CREDIT SCRUTINY PRESSURE

Two hours into the trading session, Nu Holdings trades slightly lower, down one percent. Reuters reports emerging scrutiny over rapid credit limit increases in Brazil, even as analysts evaluate the digital lender's long-term value profile.

NFLX — TECH SESSION DRIFT

We are two hours into the session and Netflix is down nearly two percent on muted volume. With no company-specific catalysts on the wire today, the streaming leader is tracking broader tech market sentiment.

MSFT — MIDDAY TECH RETREAT

Two hours into the trading day, Microsoft is dipping just over one percent. Absent any fresh headlines this morning, the tech giant is consolidating alongside broader mega-cap indexes as trading moves toward midday.

GOOGL — STEADY TECH RESILIENCE

Two hours into trading and Alphabet is holding green, up nearly one percent. With no major corporate catalysts released this morning, shares are quietly demonstrating steady relative strength across the mega-cap tech cohort.

Watchlist & Next Steps

Heading into the close, three distinct setups to monitor: Viking at $85 is your line in the sand—hold there and the path to $95 opens up. On Holding, watch $40.50; a close above today's VWAP confirms the re-rating. And Greenland Mines? If you're playing the momentum, the 50% retracement of today's range near $1.85 is your risk line—break that and the air gets thin fast. Set your alerts, manage your risk, and I'll see you at the closing bell.